Beam Therapeutics Inc.
Clinical trials sponsored by Beam Therapeutics Inc., explained in plain language.
-
Gene-Editing shot aims to fix lung and liver damage in rare disease
Disease control Recruiting nowThis study tests a new gene-editing treatment called BEAM-302 for adults with Alpha-1 antitrypsin deficiency, a genetic condition that can cause lung and liver disease. The therapy is given as an infusion and aims to correct the faulty gene. The trial will enroll 106 people to ch…
Phase: PHASE1, PHASE2 • Sponsor: Beam Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Gene therapy Follow-Up: 15-Year watch for sickle cell patients
Disease control Recruiting nowThis long-term follow-up study tracks 50 patients with sickle cell disease who received the experimental gene therapy BEAM-101. The goal is to monitor safety, side effects, and overall health for up to 15 years after treatment. Participants will have regular check-ups to see how …
Sponsor: Beam Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Gene therapy breakthrough aims to control rare metabolic disease
Disease control Recruiting nowThis study tests a new gene therapy called BEAM-301 in 36 adults with glycogen storage disease type Ia (GSDIa) who have a specific gene change. The goal is to see if a single dose can safely improve blood sugar control and reduce the need for cornstarch supplements. Participants …
Phase: PHASE1, PHASE2 • Sponsor: Beam Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New antibody BEAM-103 enters first human safety trial
Knowledge-focused Recruiting nowThis early-stage trial is testing a new drug called BEAM-103, a monoclonal antibody, in 30 healthy adults aged 18 to 55. Participants receive a single intravenous dose of either BEAM-103 or a placebo and are monitored for up to 4 months. The main goal is to check the drug's safet…
Phase: PHASE1 • Sponsor: Beam Therapeutics Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC